Delayed-onset caspase-dependent massive hepatocyte apoptosis upon fas activation in bak/bax-deficient mice

Hepatology

Volumn 54, Issue 1, 2011, Pages 240-251

  Hikita, Hayato ^a   Takehara, Tetsuo ^a   Kodama, Takahiro ^a   Shimizu, Satoshi ^a   Shigekawa, Minoru ^a   Hosui, Atsushi ^a   Miyagi, Takuya ^a   Tatsumi, Tomohide ^a   Ishida, Hisashi ^a   Li, Wei ^a   Kanto, Tatsuya ^a   Hiramatsu, Naoki ^a   Shimizu, Shigeomi ^b   Tsujimoto, Yoshihide ^a   Hayashi, Norio ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CYCLOPHILIN D; CYTOCHROME C; FAS ANTIGEN; PROTEIN BAK; PROTEIN BAX;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA STRAND BREAKAGE; GENE INACTIVATION; GENE REPRESSION; LIVER CELL; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD95; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASES; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; HEPATOCYTES; IMIDAZOLES; INDOLES; LIVER FAILURE, ACUTE; MALE; MICE; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 79959565020     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24305     Document Type: Article

References (37)

1. Guicciardi M, Gores G. Life and death by death receptors. FASEB J 2009; 23: 1625-1637.
2. Malhi H, Guicciardi M, Gores G. Hepatocyte death: a clear and present danger. Physiol Rev 2010; 90: 1165-1194.
3. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. HEPATOLOGY 1994; 19: 1354-1359.
4. Hayashi N, Mita E. Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis. J Viral Hepat 1999; 6: 357-365.
5. Feldstein A, Canbay A, Angulo P, Taniai M, Burgart L, Lindor K, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443.
6. Ryo K, Kamogawa Y, Ikeda I, Yamauchi K, Yonehara S, Nagata S, et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 2000; 95: 2047-2055.
7. Feldmann G, Lamboley C, Moreau A, Bringuier A. Fas-mediated apoptosis of hepatic cells. Biomed Pharmacother 1998; 52: 378-385.
8. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003; 195: 158-167.
9. Tait S, Green D. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-632.
10. Yin X, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886-891.
11. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK, et al. The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell 2007; 129: 423-433.
12. Lindsten T, Ross A, King A, Zong W, Rathmell J, Shiels H, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-1399.
13. Takehara T, Tatsumi T, Suzuki T, Rucker EB, 3rd, Hennighausen L, Jinushi M, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004; 127: 1189-1197.
14. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434: 652-658.
15. Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. HEPATOLOGY 2009; 50: 1217-1226.
16. Hikita H, Takehara T, Kodama T, Shimizu S, Hosui A, Miyagi T, et al. BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. HEPATOLOGY 2009; 50: 1972-1980.
17. Wang K, Yin X, Chao D, Milliman C, Korsmeyer S. BID: a novel BH3 domain-only death agonist. Genes Dev 1996; 10: 2859-2869.
18. Yamagata H, Shimizu S, Nishida Y, Watanabe Y, Craigen WJ, Tsujimoto Y. Requirement of voltage-dependent anion channel 2 for pro-apoptotic activity of Bax. Oncogene 2009; 28: 3563-3572.
19. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
20. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001; 97: 1378-1387.
21. Antonsson B, Montessuit S, Sanchez B, Martinou J. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001; 276: 11615-11623.
22. Kim T, Zhao Y, Barber M, Kuharsky D, Yin X. Bid-induced cytochrome c release is mediated by a pathway independent of mitochondrial permeability transition pore and Bax. J Biol Chem 2000; 275: 39474-39481.
23. Schüngel S, Buitrago-Molina L, Nalapareddy P, Lebofsky M, Manns M, Jaeschke H, et al. The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers. HEPATOLOGY 2009; 50: 1558-1566.
24. Huang DC, Hahne M, Schroeter M, Frei K, Fontana A, Villunger A, et al. Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proc Natl Acad Sci U S A 1999; 96: 14871-14876.
25. Fujita E, Egashira J, Urase K, Kuida K, Momoi T. Caspase-9 processing by caspase-3 via a feedback amplification loop in vivo. Cell Death Differ 2001; 8: 335-344.
26. Deveraux Q, Reed J. IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
27. Jost P, Grabow S, Gray D, McKenzie M, Nachbur U, Huang D, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009; 460: 1035-1039.
28. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-495.
29. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
30. Baines C, Kaiser R, Purcell N, Blair N, Osinska H, Hambleton M, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434: 658-662.
31. Caserta T, Smith A, Gultice A, Reedy M, Brown T. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 2003; 8: 345-352.
32. Wei M, Zong W, Cheng E, Lindsten T, Panoutsakopoulou V, Ross A, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-730.
33. Walter D, Schmich K, Vogel S, Pick R, Kaufmann T, Hochmuth F, et al. Switch from type II to I Fas/CD95 death signaling on in vitro culturing of primary hepatocytes. HEPATOLOGY 2008; 48: 1942-1953.
34. Schmich K, Schlatter R, Corazza N, Ferreira KS, Ederer M, Brunner T, et al. Tumor necrosis factor α sensitizes primary murine hepatocytes to Fas/CD95-induced apoptosis in a Bim- and Bid-dependent manner. HEPATOLOGY 2011; 53: 282-292.
35. Cardier JE, Schulte T, Kammer H, Kwak J, Cardier M. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells. FASEB J 1999; 13: 1950-1960.
36. Baskin-Bey E, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, et al. Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant 2007; 7: 218-225.
37. Pockros P, Schiff E, Shiffman M, McHutchison J, Gish R, Afdhal N, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. HEPATOLOGY 2007; 46: 324-329.